New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
about
The Race Is On To Shorten the Turnaround Time for Diagnosis of Multidrug-Resistant TuberculosisMicroscopic-observation drug-susceptibility assay for the diagnosis of drug-resistant tuberculosis in Harare, ZimbabweCorrelation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility resultsA Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, RussiaA Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe.The pyrazinamide susceptibility breakpoint above which combination therapy fails.Re-evaluation of the critical concentration for ethambutol antimicrobial sensitivity testing on the MGIT 960.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Reply to "breakpoints and drug exposure are inevitably closely linked"Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityPharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium DiseaseHigh rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China.Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary DiseaseMoxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.Serum drug concentrations predictive of pulmonary tuberculosis outcomes.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.Pharmacologic considerations in use and development of antituberculosis drugs.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Rifampicin Resistance: Fitness Costs and the Significance of Compensatory Evolution.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.
P2860
Q26785997-61CFC002-A491-444B-9961-B23EBBB03A26Q28486123-AE552006-6448-4B19-BB26-B5D21D9DAD99Q28540488-39F23DA9-E410-43D1-80F3-BE11510D69BAQ28554618-1D89EA5D-2745-44FA-8094-056FF548F6FEQ30275728-AC35AFB5-0E26-431E-B94E-B6A124B95D30Q33745972-60A99FF2-1EFD-4B19-8E85-4DD644953A97Q34034401-35F7A905-DD6E-4B77-AB79-7445FD9AE5B3Q34259008-ABB361C6-8CBA-491F-A37A-195920157B64Q34298988-02B2A512-045C-498C-A0AC-B77DCBF5A615Q34922554-32D773CE-1C65-4CDE-9C05-4E734682C2E3Q35106037-48FE0D5C-7A6A-4678-B4C4-295AFCE88313Q35169089-8B79DA4C-A001-418A-8125-CD7530B7A071Q35364313-2AADAFEB-166C-4C8A-B284-3AA655D5228AQ35532853-D90FF6F3-F077-41E8-A25F-CD9ED37D3D7DQ35666457-5E1D2CD2-0E4A-40AE-9BC4-1E47013A1F2DQ35844623-13D4193C-C2D0-46EA-B279-B9A2D986BDD9Q35867681-5EB80FCF-0602-472E-9098-9F3896FFA561Q35960852-57872A24-CCE9-4B8F-8DE8-A493714539D8Q36644647-4EEC8492-0BE4-4604-802F-321841A81865Q36730088-11E682AA-0562-4800-B8C7-99DF8DFD1596Q36864780-20B983FB-7A85-4E6F-BCFD-01EBA0DFFEF4Q36887811-122AFD46-08DF-4725-9557-3255036092E3Q36933441-7A27AC8D-708D-4660-8DB2-6B40345D2118Q37119998-34E5916D-9C57-4BB6-9D53-8F4AFB10BE75Q37213037-CFF45F3C-ED57-451F-9B3B-9D3B3B4F4A0CQ37799461-1530333A-C8F6-4C57-9B1E-042DFFDED11DQ37942644-D07AA594-E6B4-49FA-B68F-A7AB12DE5439Q38252559-06E3E23F-47F8-4134-BB47-2B98BE1F701AQ38502298-FC2858B0-9238-472C-8E06-8A9E7E5DEAA6Q38565072-2F7B3ED4-C297-4134-B6EF-41F2E7E209FCQ38763608-AD00FD87-47F3-466D-83F3-DE184969955DQ38793891-ABCD1FED-129D-4942-9A92-E4CE440404DFQ38845761-ED502E8B-CF7A-4CD0-8786-7B8254A2F07BQ38865905-1FDD4FDE-E3C4-44F6-B6CD-6947DF21A95BQ38979626-2963BD37-E497-4AC4-B9C9-7181443F164DQ39038482-B6FF8717-99E6-4D93-9CF9-726B291D8CFDQ40065397-96758751-72F5-4587-9E00-EC41247640FBQ40679730-6B7A02E0-8D78-448C-9285-4EE3D156CDF4Q41082086-0F8F8EBB-9433-4D82-9A4B-5D167BDDB228Q41105755-BFBBDD89-24DD-45A3-A9B3-E5D77F0D2198
P2860
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
New susceptibility breakpoints ...... n pharmacokinetic variability.
@en
New susceptibility breakpoints ...... n pharmacokinetic variability.
@nl
type
label
New susceptibility breakpoints ...... n pharmacokinetic variability.
@en
New susceptibility breakpoints ...... n pharmacokinetic variability.
@nl
prefLabel
New susceptibility breakpoints ...... n pharmacokinetic variability.
@en
New susceptibility breakpoints ...... n pharmacokinetic variability.
@nl
P2860
P356
P1476
New susceptibility breakpoints ...... n pharmacokinetic variability.
@en
P2860
P304
P356
10.1128/AAC.01474-09
P407
P577
2010-01-19T00:00:00Z